All Episodes
Decera Clinical Education Oncology Podcast — 251 episodes
Incorporating AKT1 and PIK3CA Pathway Testing and Targeted Therapies in the Management of Advanced Endocrine-Resistant Breast Cancer
Personalizing EGFR Mutation–Positive NSCLC Care: Strategies for the Advanced Practice Provider
Advancing the Early Detection of Lung Cancer: Expanding Screening Access, Eligibility, and Awareness
HNSCC: Current and Emerging Therapeutic Strategies
Navigating Relapsed/Refractory Multiple Myeloma: Real-world Use of Bispecific Antibodies
Oncologists “On Call”: Our Practical Experiences to Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma
Thrombotic Events and ET/PV: What You Should Know
Global Experts Discuss Current and Emerging Treatments for ET and PV
Global Experts Discuss Diagnostic Considerations in ET and PV
Experts Discuss Novel Approaches to First-line Therapy for HER2-Positive Metastatic Breast Cancer
Patient Voices: Caring for the Whole Patient and Personalizing Treatment of Early Breast Cancer to Achieve Equitable Outcomes
Role of AKT and PI3K Inhibitors in Patients With HR-Positive Breast Cancers: Experts Share Their Thoughts on Current Practice and Future Opportunities
Patient-Centered Management of CDK4/6 Inhibitor Therapy: Adverse Event Mitigation, Adherence, and Persistence in HR+/HER2- Breast Cancer
TROP2-Directed Antibody–Drug Conjugates in Non-Small-Cell Lung Cancer: Current Use in Clinical Practice and Future Directions
Emerging Therapies for Patients With HER2+ Gastroesophageal Adenocarcinoma and Biliary Tract Cancer
Experts Discuss ADCs for HER2-Negative/Ultralow/Low MBC
Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Colorectal Cancer
Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Prostate Cancer
Bladder Cancer Breakthroughs: New NMIBC Therapies and EV + Pembrolizumab Updates From ASCO GU 2026
Myth vs Medicine: Pharmacist’s Perspective on Adjuvant CDK4/6 Inhibitor Optimization
From ASH 2025 to the Clinic: Global Perspectives on Evolving BTK Therapies in Relapsed/Refractory CLL
2025 San Antonio Breast Cancer Symposium Conference Coverage: Highlights Podcast
Advancing KRAS G12C-Targeted Therapies in NSCLC: Current Evidence and Future Directions
Beyond Chemotherapy in ALL: Emerging Bispecific Antibodies, CAR T-cell Therapies, and Evolving Treatment Strategies
Experts Discuss Novel RAS-Targeted Therapy for Pancreatic Cancer
Advanced Practice Professionals Discuss Biomarker Testing in Patients With Solid Tumors: Lung Cancer
Individualized Hemophilia Care With Hemostatic Rebalancing Therapies
Experts Offer Guidance on Shared Decision-making in the Management of Patients With PV/ET
Experts Discuss CELMoD Agents for Treating Multiple Myeloma
PulseCast: Highlights in MDS/MPNs From the 2025 ASH Annual Meeting
Expert Highlights From the 2025 World Conference on Lung Cancer
PulseCast: Highlights in Multiple Myeloma From the 2025 ASH Annual Meeting
PulseCast: Highlights in Lymphomas From the 2025 ASH Annual Meeting
PulseCast: Highlights in Nonmalignant Blood Disorders From the 2025 ASH Annual Meeting
PulseCast: Highlights in Leukemias From the 2025 ASH Annual Meeting
TROP2 and TIGIT Therapies for Advanced NSCLC: Where Are We Today?
A Newly Approved Targeted Combination Therapy for KRAS-Mutant Low-Grade Serous Ovarian Cancer
CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: A Promising Treatment Approach
Transforming Care in Cutaneous Squamous Cell Carcinoma: Integrating Immunotherapy Into Patient Care
Paroxysmal Nocturnal Hemoglobinuria: Translating Pathobiology Into Modern Clinical Management
Advancing the Care of Patients With High-Risk HR-Positive/HER2-Negative Early Breast Cancer
Advancing the Care of Patients With HR-Positive/HER2-Negative Metastatic Breast Cancer
HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancers: Testing Recommendations and New Treatment Options
Key Decisions for Selecting Bispecific Antibodies in Follicular Lymphoma
Pancreatic Cancer Progress: Expert Insights on Treatment Choices and Collaborating with Patients
Latest Advances in CAR T-Cell Therapy for Lymphomas and Multiple Myeloma
CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Experts Answer Your Questions
Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas
Available and Emerging Subcutaneous Immunotherapy Treatment Options for Patients With Cancer: A Pharmacy Perspective
Key Advances in Lymphomas and Acute Lymphocytic Leukemia From EHA and ICML 2025
Experts Discuss Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ASCO Annual Meeting
Takeaways From a Large Educational Program on Available and Emerging Treatment Options for HER2-Positive mBC
A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?
BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025
Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma
Personalized Pathways: Redefining Frontline Hodgkin Lymphoma Treatment Strategies
Experts Discuss CELMoDs in Myeloma
Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities
Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications
Taking a New Path: Evaluating Clinical Data With HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecological Malignancies
The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer
The Lay of the Land: Overview of Biology of HER2 in Genitourinary, Gastrointestinal, and Gynecologic Malignancies
Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC
Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer
Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting
Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer
Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies
Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations
ESMO 2024 Congress Highlights in Gynecologic Cancer: New Data Informing Treatment of Ovarian, Endometrial, and Cervical Cancers
A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance
Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC
Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC
ROS1-Alterations and Molecular Testing in Advanced NSCLC
Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs
Current Clinical Practice and NCCN Guidelines for CLL/SLL
Congress to Clinic: Expert Takeaways on Emerging Data for MPNs
CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways
Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
Congress to Clinic: Expert Takeaways on Emerging Data for AML
Congress to Clinic: Expert Takeaways on Emerging Data for MDS
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer
Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer
Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer
Current Considerations for Adverse Event Management With HER3-Directed Agents
Unpacking the Potential of HER3-Targeted Therapy in NSCLC
Recent Advances in ADCs and Rationale for HER3 as a Target in Lung Cancer
Expert Insight on Seminal New Clinical Trial Data Presented at the 2023 IGCS Conference Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
Novel Emerging Investigational Treatment Strategies for Patients With Myelofibrosis
A Year in Review and a Look to the Future: BTKi in CLL and MCL
Expert Insight on Key Updates and New Clinical Trial Data From the ESMO 2023 Congress Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
Expert Insights and Considerations for Precision Care With HER3-Targeted Agents in NSCLC and Breast Cancer
Improving Care for Black Patients With Endometrial Cancer
Expert Insight on Key Updates and New Clinical Trial Data From the ESGO 2023 Congress Informing Treatment for Cervical, Ovarian, and Endometrial Cancers
New Evidence With BTK Inhibitor Therapy in CLL and MCL From SOHO 2023
New Evidence With BTK Inhibitor Therapy in MCL From ICML 2023
New Evidence With BTK Inhibitor Therapy in CLL From EHA 2023
Expert Insight on Key Updates and New Clinical Trial Data From the 2023 ASCO Annual Meeting, Informing Treatment for Cervical, Ovarian, and Endometrial Cancers
Expert Insight on New Data From SGO 2023 Informing Treatment for Endometrial, Cervical, and Ovarian Cancers
Practical Insights on Using BCMA-Targeted Therapies in Multiple Myeloma
Contemporary Approaches to Treating Myelofibrosis: A Conversation Between Experts
BRCA Testing and Adjuvant Therapy in Early Breast Cancer: Experiences and Challenges
Experts Discuss Claudin 18.2: A New Target for Precision Care of Gastric and Gastroesophageal Cancers
Treatment Considerations for Patients With Essential Thrombocythemia: A Conversation Between Experts
FAQs on the Use of Asparaginase Therapy in Young and Older Adults With Acute Lymphoblastic Leukemia
Experts Answer Questions on the Management of Patients With T-Cell Lymphomas
Experts Answer Questions on Personalized Management of Patients With Myelodysplastic Syndromes
Individualizing Care for Patients With Triple-Negative Breast Cancer
Contemporary Approaches to Treating Polycythemia Vera: A Conversation Between Experts
HCC Surveillance: Challenges and Opportunities
A Patient’s Perspective on Effective Communication With the Healthcare Team: My Journey With High-Risk HR-Positive/HER2-Negative Early Breast Cancer
Expert Thoughts on Studies of Interest Presented at the 2022 ESGO Annual Meeting on Gynecologic Cancers
The Transgender Cancer Experience: A Conversation Between an Oncologist and a Transmasculine Individual on Navigating the Healthcare System
Evolving Role of BTK Inhibitors in CLL: Experts Answer Your Questions
New Evidence With BTK Inhibitor Therapy in CLL and MCL From the SOHO 2022 Annual Meeting
Expert Thoughts on Key Trials of Interest for Ovarian and Cervical Cancer at the IGCS 2022 Annual Global Meeting
Relapsed/Refractory Myeloma: Navigating the Complex Treatment Landscape
Expert Insights on Key Updates From the 2022 ESMO Congress on PARP Inhibitors in Ovarian Cancer
Managing EGFR-Mutated Non-Small-Cell Lung Cancer in Today’s Clinic: Expert Answers to Frequently Asked Questions
New Evidence With BTK Inhibitor Therapy in CLL and MCL From the Pan Pacific Lymphoma Conference 2022
Experts Discuss Challenges in Advanced Hepatocellular Carcinoma Management
HER2-Positive Breast Cancer: Current Approaches for Quality Care
New Evidence With BTK Inhibitor Therapy in CLL and MCL From EHA 2022
New Evidence With BTK Inhibitor Therapy in CLL and MCL From ASCO 2022
Expert Insights on New Data From ASCO 2022 Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
Expert Insight on Key Data From SGO 2022 Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
Call to Action and Reflection: Inclusive, Compassionate, and High-Quality Healthcare for Transgender Individuals
Inclusive Healthcare for Transgender Individuals: Insights From a Healthcare Professional’s Transition Experience
Anti-TIGIT Therapy: Overview of Current Clinical Evidence and Key Ongoing Trials
Targeting TIGIT: Understanding New Approaches for Inhibiting the Immune Checkpoint Pathway
Evolving Treatment Landscape With Regorafenib and TAS-102 in Metastatic Colorectal Cancer
Expert Answers to Key Questions on Current and Emerging BTK Inhibitor Therapies for CLL and MCL
Expert Insights on Optimal Current Management of Patients With Cholangiocarcinoma
Cancer Conversations: 3 Case Challenges of Real Patients With Myelodysplastic Syndromes
Expert Insights on Targeted Therapies for Advanced Systemic Mastocytosis
Advances in B-Cell Lymphomas: Understanding Current Treatment Approaches
TKIs for Advanced HCC in the Second Line and Beyond
New Directions With PARP Inhibitors in Pancreatic Cancer
Evolving Therapy for Myeloma: Experts Discuss Patient Case Examples
Expert Insights on Advances in Immune Thrombocytopenia
Precision Medicine for aTTP: Expert Answers to Your Questions
Precision Medicine for T-Cell Lymphomas: Expert Answers to Your Questions
Multidisciplinary Overview of EGFR-Mutated NSCLC: An Expert Panel Discussion From Biomarker Testing to Managing Progressive Disease
Experts Answer Questions on Current and Emerging Options for Hemophilia A Management
Strategies for Secondary AML and Emerging Therapies for AML
Induction and Maintenance Therapy for Fit Patients With AML Without Targetable Mutations
Targeted Treatment Options for Patients With AML and FLT3 or IDH1/2 Mutations
An Overview of AML and Treatment Strategies for Patients Unfit for Intensive Therapy
Managing Lower-Risk Myelodysplastic Syndrome: Nursing Implications
Managing Higher-Risk and Relapsed/Refractory Myelodysplastic Syndromes: Nursing Implications
Key Factors Influencing Later-Line Treatment Selection for Patients With Metastatic Colorectal Cancer
The Evolving Role of TKIs in First-line Treatment of Advanced HCC
Expert Insight on Important Clinical Trial Data From ESGO 2021 Informing Treatment for Ovarian Cancer and Endometrial Cancers
Experts Answer FAQs on Immunotherapy for Non-Small-Cell Lung Cancer
Overcoming Acquired Resistance With Second-Generation TRK Inhibitors
Role of TKIs in Nonadipocytic Soft Tissue Sarcoma and Advanced Osteosarcoma
PARP Inhibitors in Pancreatic Cancer: Experts Discuss Importance of Testing for Biomarkers Along With Current Treatment Landscape
Optimal Dosing Strategies With Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer
First-Generation TRK Inhibitors: Clinical Evidence and Indications
PARP Inhibitors in Ovarian Cancer: Experts Discuss Patient Cases and the Current Paradigm
Counseling Patients and Caregivers on Prophylaxis Therapy for Severe Hemophilia A
Rationale for NTRK Testing in Patients With Cancer
Expert Answers to HCP Questions on Androgen Deprivation Therapy for Prostate Cancer
Expert Insight on Important Clinical Trial Data From ESMO 2021 Informing Treatment for Endometrial and Ovarian Cancer
Expert Insight on New Evidence Poised to Change the Treatment Landscape in Melanoma
Expert Insight on Practice Changing From IGCS 2021 Informing Treatment for Endometrial, Ovarian, and Cervical Cancer
Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma: Experts Address FAQs
Expert Insights on Optimal Use of CDK4/6 Inhibitors for HR-Positive/HER2-Negative Breast Cancer
Essential Biomarker Testing in GI Cancers
CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Expert Answers to Clinician Questions
The Latest Advances and Guidance in Nonmetastatic Castration-Resistant Prostate Cancer
Managing Serious Adverse Events Associated with BTK Inhibitor Treatment
Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 2: Patient Strategies for Self-Management
Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 1: Drug–Drug and Drug–Food Interactions
Adverse Events Associated with BTK Inhibitor Treatment
BTK Inhibitors in CLL and Lymphomas: Overview and Current Indications
Radiopharmaceuticals in the Treatment of Metastatic Castration-Resistant Prostate Cancer
How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on BCMA-Targeted Therapies
Expert Answers to HCP Questions on CAR T-Cell Therapy
How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on Selinexor, Venetoclax, and Melphalan Flufenamide
Treatment Options for Patients With Multiple Myeloma After First Relapse
Caring for Patients With Newly Diagnosed Multiple Myeloma
Precision Medicine in Gynecologic Cancers: Expert Answers to Your Questions
Expert Answers to Questions on Managing Neurofibromatosis Type 1 and MEK Inhibitors for NF1-Associated Plexiform Neurofibromas
Expert Answers to Questions on PARP Inhibitor Combinations in Prostate Cancer
Immunotherapy for Advanced HCC: Current Options and Expert Answers to Clinician Questions
Expert Insight on Key Data From ASCO 2021 Informing Treatment for Endometrial, Ovarian, and Cervical Cancer
Optimizing Therapy for Relapsed/Refractory Multiple Myeloma: Expert Answers to Your Questions
Experts Answer FAQs on Biomarker-Driven Therapy for Non-Small-Cell Lung Cancer
Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC
Immunotherapy for Advanced HCC: Case Series
Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Germany
Managing Toxicities Associated With FGFR Inhibitors in Urothelial Cancer and Beyond
Optimizing the Timing and Sequencing of Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer
Expert Answers to Questions on Contemporary Management of Multiple Myeloma
Combining PARP inhibitors With Other Treatments for Men With Prostate Cancer: Clinical Trial Updates
Rationale for Combining PARP Inhibitors With Other Therapies in Prostate Cancer
Expert Insight on Key Data From SGO 2021 Informing Treatment for Endometrial and Ovarian Cancer
Expert Answers to Questions on PARP Inhibition for Prostate Cancer
Expert Insights on Highlights From ASH 2020 on Lymphomas/CLL
Improving Outcomes in EGFR-Mutated Non-Small-Cell Lung Cancer: Global Insights on Evolving Practice Standards
Targeting FGFR in Urothelial Cancer and Beyond
Expert Answers to HCP Questions on Pancreatic Cancer Treatment
Expert Answers to HCP Questions on CAR T-Cell Therapies in Lymphoma
Frequently Asked Questions on Emerging Antibody–Drug Conjugates in the Treatment of Advanced Non-Small-Cell Lung Cancer
Expert Answers to HCP Questions on CAR T-Cell Therapies in Myeloma and Management of Key Toxicities
Expert Insights on Highlights From ASH 2020 on Multiple Myeloma
Expert Insights on Key Data From ASH 2020 on Acute and Chronic Leukemias
Expert Insight on Key Data From WCLC 2020 in Early-Stage Lung Cancer
Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Argentina
Expert Insights on Key Data From ASH 2020 on Nonmalignant Hematologic Disorders
Expert Insights on Key Data From ASH 2020 on Myelodysplastic Syndromes and Myeloproliferative Neoplasms
Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Italy
Expert Answers to Questions on Contemporary Management of Hemophilia A
Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From the United States
An Expert Overview of Immunotherapy for Advanced HCC
Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Spain
Expert Answers to Pathologist Questions on New Biomarkers for Precision Therapy in Lung Cance
Application of Individualized Treatment for CLL/SLL: Novel Agents, Combinations, and Sequencing Therapy: FAQ
Practical Insights on Key Data From ESMO 2020 Informing Precision Medicine in NSCLC
Immunotherapy for Advanced HCC: Experts Answer Clinician Questions
Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From the Netherlands and the United Kingdom
Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From France
Molecular Classification of Endometrial Carcinoma in the Clinic Today
Advances in Immunotherapy for Endometrial Cancer
Biomarkers in Ovarian Cancer: Expert Discussion of Options for First-line Maintenance Therapy
Developments in Acute Leukemias: Expert Answers to Clinician Questions
Biomarkers in Ovarian Cancer: Expert Discussion of BRCA Testing and Beyond
Experts Discuss Evolving State-of-the-Art Management of Patients With HER2-Positive MBC
The Art of Medicine: Clinical Considerations for Patients With Advanced RCC
Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 1
Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 3
Clinical Considerations for <em>RET</em> Fusion–Positive NSCLC
Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 2
CAR T Cell Therapy for Lymphoma, Leukemia, and Myeloma: Experts Answer Clinician Questions
Practical Application of Immuno-Oncology in RCC: Expert Discussion of Second-line Therapy and Beyond
FAQ on New Therapeutic Developments in Relapsed/Refractory Multiple Myeloma
New Advances in Relapsed/Refractory Multiple Myeloma: Frequently Asked Questions on Current and Emerging Treatments
Practical Application of Immuno-Oncology in RCC: Expert Discussion of Frontline Therapy
Application of New Data in B-Cell Malignancies From ASCO and EHA 2020: Waldenström Macroglobulinemia, Mantle Cell Lymphoma, Hodgkin Lymphoma, and Diffuse Large B-Cell Lymphoma
MET Exon 14 Mutation–Positive NSCLC: FAQ Part 1
MET Exon 14 Mutation–Positive NSCLC: FAQ Part 2
Immunotherapy in SCLC: FAQ on Current Best Practice and Emerging Therapeutic Strategies
Application of New Data in B-Cell Malignancies From ASCO and EHA 2020: CLL
Future Treatment Strategies for Acute Myeloid Leukemia—Emerging Targeted Therapy Combinations and Beyond
Tumor Agnostic TRK Inhibitor Therapy and NTRK Fusion Testing: Experts Answer Clinician Questions
Improving Outcomes for Patients With CML With TKIs: FAQ Podcast
Application of Existing and Emerging Biomarkers for Immuno-Oncology Across Tumor Types: Answering Clinician Questions
Precision Therapy in Lung Cancer: FAQ on Biomarker Testing and Targeted Therapies
Precision Therapy in Lung Cancer: FAQ on Biomarkers for Immune Checkpoint Inhibitors